EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
|
osimertinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
|
dacomitinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR exon 19 deletion
|
Lung Non-Squamous Non-Small Cell Cancer
|
osimertinib Sensitive: A2 - Guideline
|
osimertinib Sensitive: A2 - Guideline
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR inhibitor Sensitive: B - Late Trials
|
EGFR inhibitor Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
LUAD
|
EGFR exon 19 deletion
|
LUAD
|
gefitinib Sensitive: B - Late Trials
|
gefitinib Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
icotinib Sensitive: B - Late Trials
|
icotinib Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib + rivoceranib Sensitive: B - Late Trials
|
gefitinib + rivoceranib Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR exon 19 deletion
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
LUAD
|
EGFR exon 19 deletion
|
LUAD
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib + ramucirumab Sensitive: B - Late Trials
|
gefitinib + ramucirumab Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
Lung Non-Small Cell Squamous Cancer
|
EGFR exon 19 deletion
|
Lung Non-Small Cell Squamous Cancer
|
EGFR inhibitor Sensitive: B - Late Trials
|
EGFR inhibitor Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
aumolertinib Sensitive: B - Late Trials
|
aumolertinib Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
furmonertinib Sensitive: B - Late Trials
|
furmonertinib Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
LUAD
|
EGFR exon 19 deletion
|
LUAD
|
osimertinib Resistant: C1 - Off-label
|
osimertinib Resistant: C1 - Off-label
|
EGFR exon 19 deletion
|
Small Cell Lung Cancer
|
EGFR exon 19 deletion
|
Small Cell Lung Cancer
|
gefitinib Sensitive: C1 - Off-label
|
gefitinib Sensitive: C1 - Off-label
|
EGFR exon 19 deletion
|
Lung Cancer
|
EGFR exon 19 deletion
|
Lung Cancer
|
gefitinib Sensitive: C1 - Off-label
|
gefitinib Sensitive: C1 - Off-label
|
EGFR exon 19 deletion
|
Small Cell Lung Cancer
|
EGFR exon 19 deletion
|
Small Cell Lung Cancer
|
osimertinib Sensitive: C1 - Off-label
|
osimertinib Sensitive: C1 - Off-label
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria
|
osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
anlotinib + icotinib Sensitive: C2 – Inclusion Criteria
|
anlotinib + icotinib Sensitive: C2 – Inclusion Criteria
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
amivantamab-vmjw Sensitive: C2 – Inclusion Criteria
|
amivantamab-vmjw Sensitive: C2 – Inclusion Criteria
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
EGF816 Sensitive: C2 – Inclusion Criteria
|
EGF816 Sensitive: C2 – Inclusion Criteria
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria
|
amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
U3-1402 Sensitive: C2 – Inclusion Criteria
|
U3-1402 Sensitive: C2 – Inclusion Criteria
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
erlotinib + anlotinib Sensitive: C3 – Early Trials
|
erlotinib + anlotinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
camrelizumab + rivoceranib Resistant: C3 – Early Trials
|
camrelizumab + rivoceranib Resistant: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
afatinib + DFP-14323 Sensitive: C3 – Early Trials
|
afatinib + DFP-14323 Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib + durvalumab Resistant: C3 – Early Trials
|
gefitinib + durvalumab Resistant: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
bevacizumab + erlotinib Sensitive: C3 – Early Trials
|
bevacizumab + erlotinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
olaparib + gefitinib Sensitive: C3 – Early Trials
|
olaparib + gefitinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
ensartinib Sensitive: C3 – Early Trials
|
ensartinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
brigatinib Sensitive: C3 – Early Trials
|
brigatinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
alectinib Sensitive: C3 – Early Trials
|
alectinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
lorlatinib Sensitive: C3 – Early Trials
|
lorlatinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib + fruquintinib Sensitive: C3 – Early Trials
|
gefitinib + fruquintinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
anlotinib + APL-502 Sensitive: C3 – Early Trials
|
anlotinib + APL-502 Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib + anlotinib Sensitive: C3 – Early Trials
|
gefitinib + anlotinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
bevacizumab + osimertinib Sensitive: C3 – Early Trials
|
bevacizumab + osimertinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
LUAD
|
EGFR exon 19 deletion
|
LUAD
|
brigatinib Sensitive: C3 – Early Trials
|
brigatinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
durvalumab Sensitive: C3 – Early Trials
|
durvalumab Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
LUAD
|
EGFR exon 19 deletion
|
LUAD
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
bevacizumab + gefitinib Sensitive: C3 – Early Trials
|
bevacizumab + gefitinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion
|
Thymic Carcinoma
|
EGFR exon 19 deletion
|
Thymic Carcinoma
|
icotinib Sensitive: C4 – Case Studies
|
icotinib Sensitive: C4 – Case Studies
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: C4 – Case Studies
|
bevacizumab + atezolizumab Sensitive: C4 – Case Studies
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
erlotinib + ado-trastuzumab emtansine Sensitive: D – Preclinical
|
erlotinib + ado-trastuzumab emtansine Sensitive: D – Preclinical
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
lenalidomide Sensitive: D – Preclinical
|
lenalidomide Sensitive: D – Preclinical
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
CH7233163 Sensitive: D – Preclinical
|
CH7233163 Sensitive: D – Preclinical
|
EGFR exon 19 deletion
|
Lung Cancer
|
EGFR exon 19 deletion
|
Lung Cancer
|
BMS-722782 Sensitive: D – Preclinical
|
BMS-722782 Sensitive: D – Preclinical
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
H002 Sensitive: D – Preclinical
|
H002 Sensitive: D – Preclinical
|